全、新、優(yōu)、品、好四大特點：

磷酸化帕金蛋白抗體費用 全：公司提供上萬種產品，涵蓋了生物試劑，elisa試劑盒，標準品，培養(yǎng)基，原裝耗材，抗體、培養(yǎng)基、ATCC細胞等，基本上各種科研所需產品在我司都能找到。

新：產品更新速度較快，基本上每周都有新產品出現。

優(yōu)：產品質量好，投訴比較少。

好：我公司具有優(yōu)質的技術團隊，產品一旦售出，實驗過程中遇到困難可提供在線技術咨詢。使您使用產品時沒有任何的后顧之憂。

磷酸化帕金蛋白抗體費用 英文名稱  Anti-phospho-PARK2(Ser378)

中文名稱  磷酸化帕金蛋白抗體費用 

別    名 PARK2(phospho S378); AR JP; E3 ubiquitin protein ligase parkin; FRA6E; LPRS 2; LPRS2; PARK 2; PARK2; Parkinson disease (autosomal recessive juvenile) 2; Parkinson disease protein 2; Parkinson juvenile disease protein 2; PDJ; PRKN 2; PRKN; PRKN2; Ubiquitin E3 ligase PRKN.

產品屬性：

濃    度  1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來源  Rabbit

克隆類型   polyclonal

交叉反應   Human, Pig, Guinea Pig

產品類型   一抗 磷酸化抗體  

研究領域    免疫學 神經生物學

蛋白分子量  predicted molecular weight: 51kDa 

性    狀   Lyophilized or Liquid

免 疫 原  KLH conjugated Synthesised phosphopeptide derived from human PARK2 around the phosphorylation site of Ser378

亞    型  IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

磷酸化帕金蛋白抗體費用 產品應用   WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產品介紹 Parkinson's Disease, the second most common neurodegenerative disease after Alzheimer's Disease, is characterized by the loss of dopaminergic neurons and the presence of Lewy bodies (comprised of alpha synuclein and parkin inclusions). Autosomal Recessive Juvenile Parkinsonism (AR-JP) is a recently described form of Parkinson's Disease that has been linked to a gene that codes for parkin. Parkin, a 52 kDa protein, has a suggested role in the ubiquitin/proteasome pathway for protein degradation. The amino terminus bears sequence homology to ubiquitin while functionally it acts as a RING type ubiquitin protein ligase (E3) that coordinates the transfer of ubiquitin to substrate proteins, thus targeting them for degradation by the proteasome.

Function : Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins, such as BCL2, SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP, SEPT5, ZNF746 and AIMP2. Mediates monoubiquitination as well as 'Lys-48'-linked and 'Lys-63'-linked polyubiquitination of substrates depending on the context. Participates in the removal and/or detoxification of abnormally folded or damaged protein by mediating 'Lys-63'-linked polyubiquitination of misfolded proteins such as PARK7: 'Lys-63'-linked polyubiquitinated misfolded proteins are then recognized by HDAC6, leading to their recruitment to aggresomes, followed by degradation. Mediates 'Lys-63'-linked polyubiquitination of SNCAIP, possibly playing a role in Lewy-body formation. Mediates monoubiquitination of BCL2, thereby acting as a positive regulator of autophagy. Promotes the autophagic degradation of dysfunctional depolarized mitochondria. Mediates 'Lys-48'-linked polyubiquitination of ZNF746, followed by degradation of ZNF746 by the proteasome; possibly playing a role in role in regulation of neuron death. Limits the production of reactive oxygen species (ROS). Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin-E during neuronal apoptosis. May represent a tumor suppressor gene.

Subunit : Forms an E3 ubiquitin ligase complex with UBE2L3 or UBE2L6. Mediates 'Lys-63'-linked polyubiquitination by associating with UBE2V1. Part of a SCF-like complex, consisting of PARK2, CUL1 and FBXW7. Interacts with SNCAIP. Binds to the C2A and C2B domains of SYT11. Interacts and regulates the turnover of SEPT5. Part of a complex, including STUB1, HSP70 and GPR37. The amount of STUB1 in the complex increases during ER stress. STUB1 promotes the dissociation of HSP70 from PARK2 and GPR37, thus facilitating PARK2-mediated GPR37 ubiquitination. HSP70 transiently associates with unfolded GPR37 and inhibits the E3 activity of PARK2, whereas, STUB1 enhances the E3 activity of PARK2 through promotion of dissociation of HSP70 from PARK2-GPR37 complexes. Interacts with PSMD4 and PACRG. Interacts with LRRK2. Interacts with RANBP2. Interacts with SUMO1 but not SUMO2, which promotes nuclear localization and autoubiquitination. Interacts (via first RING-type domain) with AIMP2 (via N-terminus). Interacts with PSMA7 and RNF41. Interacts with PINK1.

Subcellular Location : Cytoplasm, cytosol. Nucleus. Endoplasmic reticulum. Mitochondrion. Note=Mainly localizes in the cytosol. Co-localizes with SYT11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. Relocates to dysfunctional mitochondria that have lost the mitochondrial membrane potential; recruitment to mitochondria is PINK1-dependent.

Post-translational modifications : Auto-ubiquitinates in an E2-dependent manner leading to its own degradation. Also polyubiquitinated by RNF41 for proteasomal degradation.

S-nitrosylated. The inhibition of PARK2 ubiquitin E3 ligase activity by S-nitrosylation could contribute to the degenerative process in PD by impairing the ubiquitination of PARK2 substrates.

DISEASE : Defects in PARK2 are a cause of Parkinson disease (PARK) [MIM:168600]. A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

Defects in PARK2 are the cause of Parkinson disease type 2 (PARK2) [MIM:600116]; also known as early-onset parkinsonism with diurnal fluctuation (EPDF) or autosomal recessive juvenile Parkinson disease (PDJ). A neurodegenerative disorder characterized by bradykinesia, rigidity, postural instability, tremor, and onset usually befor 40. It differs from classic Parkinson disease by early DOPA-induced dyskinesia, diurnal fluctuation of the symptoms, sleep benefit, dystonia and hyper-reflexia. Dementia is absent. Pathologically, patients show loss of dopaminergic neurons in the substantia nigra, similar to that seen in Parkinson disease; however, Lewy bodies (intraneuronal accumulations of aggregated proteins) are absent.

Similarity : Belongs to the RBR family. Parkin subfamily.

Contains 1 IBR-type zinc finger.

Contains 2 RING-type zinc fingers.

Contains 1 ubiquitin-like domain.

Database links : UniProtKB/Swiss-Prot: O60260.2

parkin基因的突變，患者很早就會出現氏癥的，Parkin屬于RBR蛋白家族，與泛素相關蛋白分解途徑有關.

實驗流程：

正在熱銷的相關產品：

Human 11-dehydro-thromboxane B2,11-DH-TXB2 ELISA Kit 人11去氫烷B2Multi-class antibodies規(guī)格： 48T

Anti-Resistin (human, dog) 抵抗素抗體(人，犬)Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh GZMA/Granzyme A 顆粒酶A抗體 規(guī)格 0.2ml

SP-A(Human Pulmonary surfatcant-associated protein A) ELISA Kit 人肺表面活性物質相關蛋白A 96T

Optimedin 英文名稱： 嗅球蛋白3抗體 0.2ml

BRD7 英文名稱： 相關轉錄調節(jié)蛋白抗體 0.2ml

Anti-Resistin (human, dog) 抵抗素抗體(人，犬)Multi-class antibodies規(guī)格： 0.1ml

Anti-HIV gp41/FITC 熒光素標記病毒抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Phospho-PAK4 (Ser474)/PAK5 (Ser602)/PAK6 (Ser560) /FITC 熒光素標記磷酸化p21激活激酶4、5、6抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh ATG9A 自噬相關蛋白9A抗體 規(guī)格 0.2ml

Amylin 相關肽(胰島淀粉樣肽) 0.5mg

GABA A Receptor gamma 2 英文名稱： γ基γ2受體/GABAA Rγ2抗體 0.1ml

Rhesus antibody Rh Rabbit Anti-mouse IgM/Alexa Fluor 647 Alexa Fluor 647標記的兔抗小鼠IgM 規(guī)格 0.1ml

Phospho-PAK4 (Ser474)/PAK5 (Ser602)/PAK6 (Ser560) /FITC 熒光素標記磷酸化p21激活激酶4、5、6抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Osteocalcin 小鼠骨鈣素Multi-class antibodies規(guī)格： 48T

Anti-Apo B 載脂蛋白B抗體Multi-class antibodies規(guī)格： 0.1ml

Rhesus antibody Rh Mouse Anti-rat IgG/Bio 生物素標記的小鼠抗大鼠IgG 規(guī)格 0.1ml

APCR(Human activated protein C resistance) ELISA Kit 人活化蛋白C抵抗素 96T

SLAP 英文名稱： SLAP蛋白抗體 0.1ml

C6orf192 英文名稱： 8號染色體開放閱讀框192抗體 0.2ml

Anti-Apo B 載脂蛋白B抗體Multi-class antibodies規(guī)格： 0.1ml

cycloheximide

DG-18瓊脂 DICHLORANGLYCEROL (DG-18) AGAR 用于食品中和酵母菌分離培養(yǎng)

糖發(fā)酵基礎肉湯 Bromcersol Purple Broth Base 250克 微生物檢驗中各種糖發(fā)酵實驗，無菌加入各種糖醇類物質

支原體肉湯基礎250g/瓶含酚紅，用于支原體的培養(yǎng)，使用前添加20%小牛血清及抑菌劑incubationmedia支原體肉湯基礎250g/瓶含酚紅，用于支原體的培養(yǎng)，使用前添加20%小牛血清及抑菌劑

theSmallestBrothMedium

TerrificBrothHCM00g用于提高大腸桿菌中質粒DNA的成品得率Terrificbrothisusedwithglycerolincultivatingrec...

麥康凱瓊脂 (CM0007) Oxoid incubation media 麥康凱瓊脂 (CM0007) Oxoid

滅酵母 食用酵母、產酒精。 支/瓶

TSIAgar

支原體檢測培養(yǎng)基

磷酸化帕金蛋白抗體費用 Bolton肉湯基礎  規(guī)格：  250g  用途：  用于空腸彎曲菌的選擇性增菌(GB)，每100mL基礎培養(yǎng)基需添加1支配套試劑(SR0340)

哥倫比亞瓊脂培養(yǎng)基  規(guī)格：  250g  用途：  滅菌后冷至45℃左右時加入5%脫纖維羊血，用于空腸彎曲菌的培養(yǎng)。(CP、GB、EP、USP)

腦—心浸萃液態(tài)培養(yǎng)基  規(guī)格：  100g  用途：  廣泛用于霉菌、酵母、細菌的培養(yǎng)，包括營養(yǎng)要求較高的微生物的培養(yǎng)，特別用于飲用天然礦泉水和城...

四酸亮綠增菌液  規(guī)格：  2X5支  用途：  含液2ml/支和煌綠1ml/支，2支添加于100mL（023031）中配成TTB

技術外包服務:

★磷酸化帕金蛋白抗體費用 分子生物學：質粒抽提、PCR、Q-PCR、RT-PCR、分子生物學：基因合成、引物合成、基因測序、載體構建等

★蛋白工程：原核、哺乳動物蛋白表達系統(tǒng)等

★病毒包裝：腺病毒、慢病毒等

★抗體工程：磁珠分選、病理染色、WB、ELISA、IP、IF、IHC、FACS、Confocal等等

★細胞工程：細胞表型分析(凋亡、增殖、周期、遷移、侵襲、修復、克隆形成)、細胞培養(yǎng)、細胞膜制備、穩(wěn)定細胞株構建、細胞RNAi技術等等。